Regeneron Pharmaceuticals retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $31.673B, a 16.19% increase year-over-year.
Regeneron Pharmaceuticals retained earnings (accumulated deficit) for 2024 were $31.673B, a 16.19% increase from 2023.
Regeneron Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $27.26B, a 16.96% increase from 2022.
Regeneron Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $23.307B, a 22.87% increase from 2021.